News
Announcement: Richard Sewalt new Chief Commercial Officer (CCO) at BioConnection
Oss, NL September 2, 2024 We are excited to announce that Richard Sewalt has joined BioConnection as our new Chief Commercial Officer (CCO). With his extensive background and proven expertise, Richard will be a key driver of our continued success and growth. Richard...
Announcement: Richard Sewalt new Chief Commercial Officer (CCO) at BioConnection
Oss, NL September 2, 2024 We are excited to announce that Richard Sewalt has joined BioConnection as our new Chief Commercial Officer (CCO). With his extensive background and proven expertise, Richard will be a key driver of our continued success and growth. Richard...
GMP certification for new large scale filling line
Oss, The Netherlands, June 28, 2021. BioConnection received today from the Dutch Healthcare Inspectorate (IGJ) the GMP certification and...
BioConnection is honoured to support VarmX
With the EU and US GMP capabilities from our facility in Oss, BioConnection is proud to assist VarmX to accelerate the GMP manufacturing trajectory...
AdaptVac partners with BioConnection to manufacture their COVID-19 vaccine
BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine in its...
BioConnection is honoured that AIMM Therapeutics has become our customer.
With our capabilities from our facility in Oss, the Netherlands, we are able to assist AIMM Therapeutics in the development of their groundbreaking...
Announcement: Large scale sterile GMP production capacity available for COVID-19 programs in our EMA and US-FDA certified facility
BioConnection B.V. / Oss, The Netherlands BioConnection has sterile drug product production capacity available for COVID-19 programs BioConnection...
Announcement: Sterile GMP production capacity available to overcome Covid-19 pandemic
BioConnection B.V. / Oss, The Netherlands / April 9, 2020 BioConnection has sterile production capacity available for the battle against the...